GLAXOSMITHKLINE AND VITAE ESTABLISH STRATEGIC ALLIANCE

GlaxoSmithKline and Vitae Pharmaceuticals have formed an exclusive worldwide strategic alliance to develop and commercialize novel drug compounds for the treatment of hypertension and related cardiovascular disorders. Vitae will receive an upfront payment from GSK comprised of both cash and an equity investment in Vitae. Vitae will also receive committed funding to support research activities conducted by Vitae and further payments upon the achievement of research, development and regulatory milestones.

Yahoo News (http://biz.yahoo.com/prnews/050620/phm009.html?.v=15)